Insulet (NASDAQ:PODD) Given New $365.00 Price Target at Oppenheimer

Key Points

• Oppenheimer raised its price target for Insulet (NASDAQ:PODD) from $324.00 to $365.00, suggesting a potential upside of 5.12% based on current prices and maintaining an "outperform" rating.
• Insulet reported a 32.9% increase in revenue year-over-year, with $649.10 million in quarterly revenue and earnings per share (EPS) of $1.17, exceeding analyst expectations.
• The company's stock receives a consensus rating of "Moderate Buy" from analysts, with a majority rating it as a Buy and an average target price of $335.12.

Insulet (NASDAQ:PODD - Get Free Report) had its price target upped by equities research analysts at Oppenheimer from $324.00 to $365.00 in a report issued on Monday, MarketBeat Ratings reports. The brokerage currently has an "outperform" rating on the medical instruments supplier's stock. Oppenheimer's price objective indicates a potential upside of 5.12% from the company's current price.

Other equities analysts have also recently issued research reports about the stock. Royal Bank Of Canada boosted their price target on shares of Insulet from $330.00 to $350.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Wells Fargo & Company boosted their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research note on Friday, August 8th. Canaccord Genuity Group boosted their price objective on shares of Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Finally, Raymond James Financial reissued an "outperform" rating and set a $360.00 price objective (up previously from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Sixteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $335.12.

Insulet Trading Down 0.3%

Shares of PODD stock traded down $1.20 during mid-day trading on Monday, reaching $347.24. The stock had a trading volume of 77,521 shares, compared to its average volume of 749,583. The stock's 50-day moving average price is $307.55 and its two-hundred day moving average price is $289.87. Insulet has a 52-week low of $216.00 and a 52-week high of $350.00. The firm has a market capitalization of $24.44 billion, a PE ratio of 105.54, a price-to-earnings-growth ratio of 2.92 and a beta of 1.36. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. During the same quarter in the previous year, the company earned $0.55 earnings per share. The company's revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts expect that Insulet will post 3.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Norges Bank bought a new position in Insulet during the second quarter valued at approximately $324,689,000. GAMMA Investing LLC increased its stake in shares of Insulet by 27,298.6% in the first quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock worth $1,744,100,000 after purchasing an additional 661,717 shares in the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of Insulet in the second quarter worth $131,439,000. American Century Companies Inc. increased its stake in shares of Insulet by 34.8% in the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after purchasing an additional 297,734 shares in the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Insulet in the first quarter worth $74,163,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.